摘要
动脉粥样硬化(AS)是一种慢性炎症性血管疾病,也是大多数心血管疾病的核心病理基础。血管内皮细胞作为血管内膜的单层细胞,在维持血管内壁完整性、调控血管张力、抗炎、抗血栓形成等方面发挥着首要屏障作用。因此,内皮细胞功能障碍是AS始动的重要因素。研究显示,氧化应激、炎症反应、细胞程序性死亡及细胞衰老等因素可导致内皮细胞功能障碍,促进AS的发生发展。中药活性成分具有多成分、多靶点和多通路的作用特点。对于AS,中药中的苯乙醇苷类、皂苷类、黄酮类及生物碱类化合物可通过抗氧化、抗炎、抑制内皮细胞凋亡和焦亡、改善内皮屏障功能等多途径和机制,调控血管内皮细胞功能,从而发挥抗AS作用,可为中药防治AS的临床应用提供参考。
Atherosclerosis(AS)is a chronic inflammatory vascular disease and also the core pathological basis of most cardiovascular diseases.Endothelial cells,as a single layer of cells in the inner lining of blood vessels,play a prima⁃ry barrier role in maintaining the integrity of the vascular endothelium,regulating vascular tension,anti-inflammation,and anti-thrombosis,etc.Therefore,endothelial dysfunction is a key factor in the initiation of AS.Research indicates that en⁃dothelial dysfunction,which leads to the onset and progression of AS,is promoted by factors as oxidative stress,inflamma⁃tory responses,programmed cell death and cellular senescence.The active ingredients of traditional Chinese medicine ex⁃hibit multi-target therapeutic potential against AS.Phenethyl alcohol glycosides,saponins,flavonoids,and alkaloids from traditional Chinese medicine exert effects against AS through multiple pathways and mechanisms.These include antioxi⁃dant and anti-inflammatory activities,inhibition of endothelial cell apoptosis and pyroptosis,and improvement of endotheli⁃al barrier function.This review provides traditional Chinese medicine as a promising therapeutic strategy for AS.
作者
杨学美
孙赟
黄丰
童晓云
YANG Xuemei;SUN Yun;HUANG Feng;TONG Xiaoyun(College of Pharmaceutical Sciences,Yunnan University of Chinese Medicine,Kunming 650500,China;不详)
出处
《山东医药》
2026年第1期137-141,共5页
Shandong Medical Journal
基金
国家自然科学基金项目(82360925)
云南省科技厅科技计划项目(202301AZ070001-014,20240AC350042)
云南省2020年高层次中医药领军人才项目[云卫中医发展发(2021)1号]
云南省院士专家工作站(202305AF150029)。
关键词
动脉粥样硬化
内皮细胞
氧化应激
炎症反应
atherosclerosis
endothelial cells
oxidative stress
inflammatory response
